FOLH1 and metastatic prostate carcinoma: All the patients selected for the present study had biopsy-proven metastatic prostate cancer and had undergone 18F-PSMA-1007 PET-CT (Computed Tomography) scans to ensure PSMA expression in the cancerous lesions 2-3 weeks prior to undergoing 177Lu-PSMA-617 therapy.